Collaborations

eQcell’s translational approach to development of its regenerative therapeutics bridges the initial veterinary concentration to the extension of the platform to human therapeutics. The veterinary therapy holds the prospect of rapid marketing approval and, in the process, generating data leading to a scientifically- and economically-effective pathway for continuing into similar human applications. That pathway reduces the significant risk and cost of late-stage failures in human drug development, and benefits the developer with early marketing revenues.

​

eQcell’s clinical status exhibits its leadership in the translational sciences at the industrial level, applying the principles of therapeutic development concurrently to both animal and human health.

​

eQcell is the beneficiary of partnerships with a range of acclaimed academic institutions and corporations worldwide.

​

eQcell is committed to supporting research projects by providing overhead for research contracts where indicated. The overhead support provided by our company shall not exceed 20 % of the total research contract value. This limit is established to ensure that a significant portion of the funding is directed towards the core research activities rather than administrative or indirect costs.